Chemotherapy News and Research

Latest Chemotherapy News and Research

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Methodist Hospital will soon have new brain and pituitary tumor treatment center

BD receives FDA approval for second prefilled injectable drug

BD receives FDA approval for second prefilled injectable drug

Study shows intraventricular chemotherapy increases overall survival in LMC patients

Study shows intraventricular chemotherapy increases overall survival in LMC patients

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

Researchers find deficiency in anti-tumor protein can delay DNA repair after radiation treatment

Researchers find deficiency in anti-tumor protein can delay DNA repair after radiation treatment

Oncology nurses explore how to better combat patient fatigue

Oncology nurses explore how to better combat patient fatigue

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

UB researchers develop aniontransporters to trigger cancer cell apoptosis

UB researchers develop aniontransporters to trigger cancer cell apoptosis

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Advances in treatment have improved the chances of survival for young patients with cancer

Advances in treatment have improved the chances of survival for young patients with cancer

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

New chemical compound offers a promising step for creating potential anti-cancer agents

New chemical compound offers a promising step for creating potential anti-cancer agents

Study examines link between cognitive complaints and neuropsychological testing abnormalities in breast cancer patients

Study examines link between cognitive complaints and neuropsychological testing abnormalities in breast cancer patients

Researchers find new potential target for anti-telomerase cancer therapy

Researchers find new potential target for anti-telomerase cancer therapy

Combination therapies may advance treatment for anaplastic thyroid cancer

Combination therapies may advance treatment for anaplastic thyroid cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.